Cramer’s Mad Dash: Johnson & Johnson

Summary

CNBC's Jim Cramer uses the Mad Dash to make a bullish case for Johnson & Johnson, calling it the second-best pharma after Eli Lilly and arguing the stock can go much higher. He cites its 19x earnings multiple, divestitures of Kenvue and orthopedics, a fast-growing oncology portfolio, and diminishing talc litigation risk. The discussion also touches on orthopedics as a commodity-like market and compares J&J favorably with peers such as Eli Lilly and Novartis.

• Jim Cramer delivered a bullish Mad Dash segment on Johnson & Johnson.
• Cramer called J&J the second-best pharma after Eli Lilly.
• He said J&J trades at only 19 times earnings and can go much higher.
• He cited Kenvue and orthopedics divestitures as improving the story.
• Cramer highlighted J&J's fast-growing oncology portfolio and pure-play pharma transition.
• He downplayed talc litigation risk, saying J&J is fighting cases one by one.
• Cramer described orthopedics as a commodity market with no P/E multiple.
• The co-host noted J&J had difficult years until last year and asked about another good year.